

COMMENTARY

Metformin overdose: time to move on

Jean-Christophe Orban^{1,2}, Eric Fontaine³ and Carole Ichai^{*1,2}

See related research by Protti et al., <http://ccforum.com/content/16/5/R180>

Abstract

Does metformin-associated lactic acidosis really exist? Despite an old controversy, there is no doubt about it. But do we understand what is going on? Laboratory findings raised several hypotheses explaining the pathophysiology of this disease. The main cause could be an inhibition of either gluconeogenesis or mitochondrial respiratory chain complex I. From bench to bedside, one hypothesis is now confirmed in humans. Metformin poisoning involves, at least partially, a mitochondrial dysfunction.

In this issue of *Critical Care*, Protti and colleagues [1] report the effects of metformin on human platelets both *in vitro* and *ex vivo*. *In vitro* experiments were performed on healthy platelets incubated with increasing doses of metformin, whereas *ex vivo* experiments were done on platelets from patients presenting accidental metformin-induced lactic acidosis. In both situations, platelets' lactate production and mitochondrial functions were measured. *In vitro*, a dose-dependent relationship between metformin concentration and lactate production was found. In both conditions, high levels of metformin decreased mitochondrial respiratory chain complex I activity, mitochondria polarization, and oxygen consumption. *Ex vivo* only, mitochondria respiratory chain complex IV activity declined.

Metformin is a biguanide that has been used as a first-line drug for type 2 diabetes treatment since 1957 in Europe and 1995 in the US [2]. Metformin was reputed to induce lactic acidosis, partly because phenformin, another biguanide, was withdrawn from the market because of an unacceptable rate of this complication [3]. However, numerous clinical studies reported a similar incidence of lactic acidosis in diabetic patients with or without

metformin, leading some authors to deny the existence of metformin-associated lactic acidosis [4]. However, in usual clinical practice, metformin contraindications are not often respected [5]. Moreover, physicians do not really monitor adequately their prescription. As a result, numerous publications reported the association between metformin and lactic acidosis [6,7]. When a cause of lactic acidosis such as shock state or acute renal failure is present, the responsibility of metformin could be questioned. But when healthy patients without risk factors develop metformin poisoning leading to lactic acidosis, there is no doubt about this link. However, metformin inhibits hepatic gluconeogenesis in different animal species and decreases mitochondrial respiratory chain complex I activity in different organs [8,9]. Both conditions can lead to lactate accumulation. Until recently, the clinical research on metformin-associated lactic acidosis was limited to retrospective studies describing incidence, risk factors, and supportive treatments. A big step forward was made when the Gattinoni group [10] reported a decrease in oxygen consumption after metformin poisoning in humans, strongly suggesting that metformin was able to induce mitochondrial dysfunction in humans. The study by Protti and colleagues elegantly confirms the implication of mitochondria in the pathophysiology of this disease. But it does not rule out the effects of metformin on gluconeogenesis. Further research is needed to assess the respective parts of these mechanisms.

Of course, the importance of platelet mitochondrial dysfunction *per se* has to be put in perspective. Platelets are probably not involved in lactic acidosis build-up during metformin overdose. However, as demonstrated previously in the pig, platelet mitochondrial dysfunction mirrors the mitochondrial dysfunction in other vital organs [11]. Platelets are more easily accessible than vital organs like the liver or kidney. For research purposes in humans, this approach seems to be promising to evaluate the effects of potential therapies. However, a possible limit to their findings lies in their model. It is not clear whether this model represents acute or chronic overdose. This question is important as they are considered different conditions with different prognoses [12]. Acute intentional poisoning clearly has a better outcome than accidental accumulation.

*Correspondence: ichai@unice.fr

¹Service de Réanimation Médico-chirurgicale, Hôpital Saint-Roch, Centre Hospitalier Universitaire de Nice, 5 rue Pierre Dévoluy, 06006 Nice, France
Full list of author information is available at the end of the article

Now that serious research on this rare disease has started, we can also imagine improving its care. Currently, the treatment is only supportive: increasing blood pressure with fluid infusion and catecholamines and promoting metformin elimination by renal replacement therapy. Restoring ATP production during energy failure due to mitochondria dysfunction is still challenging. New ideas could come from metabolic manipulations. In severe sepsis, another condition associated with mitochondrial dysfunction, succinate can bypass respiratory chain complex I inhibition and restore oxygen consumption [13]. In isolated cells, succinate is reputed not to cross the plasma membrane, but methyl succinate (a cell-permeant succinate) has been used to bypass metformin blockade of respiratory chain complex I [14]. This intervention led to a reduction of metformin toxicity. This strategy might be a therapeutic modality for metformin overdose in the future.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Service de Réanimation Médico-chirurgicale, Hôpital Saint-Roch, Centre Hospitalier Universitaire de Nice, 5 rue Pierre Dévoluy, 06006 Nice, France.

²IRCAN, Faculté de Médecine, Université de Nice, Avenue de Valombrose, 06107 Nice, France. ³INSERM, U1055, 2280 rue de la piscine, 38041 Grenoble, France.

Published: 25 October 2012

References

1. Protti A, Lecchi A, Fortunato F, Artoni A, Greppi N, Vecchio S, Fagioli G, Moggio M, Comi GP, Mistraletti G, Lanticina B, Faraldi L, Gattinoni L: Metformin overdose causes platelet mitochondrial dysfunction in humans. *Crit Care* 2012, **16**:R180.
2. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet* 1998, **352**:854-865.
3. Kwong SC, Brubacher J: Phenformin and lactic acidosis: a case report and review. *J Emerg Med* 1998, **16**:881-886.
4. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. *Cochrane Database Syst Rev* 2010, (4):CD002967.
5. Holstein A, Nahrwold D, Hinze S, Egberts EH: Contra-indications to metformin therapy are largely disregarded. *Diabet Med* 1999, **16**:692-696.
6. Orban JC, Giunti C, Levraud J, Grimaud D, Ichai C: Metformin-associated lactic acidosis remains a serious complication of metformin therapy. *Ann Fr Anesth Reanim* 2003, **22**:461-465.
7. Wills BK, Bryant SM, Buckley P, Seo B: Can acute overdose of metformin lead to lactic acidosis? *Am J Emerg Med* 2010, **28**:857-861.
8. Foretz M, Hébrard S, Ledlèrc J, Zarrinpasheh E, Soty M, Mithieux G, Sakamoto K, Andreelli F, Viollet B: Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. *J Clin Invest* 2010, **120**:2355-2369.
9. El-Mir MY, Nogueira V, Fontaine E, Avéret N, Rigoulet M, Leverve X: Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. *J Biol Chem* 2000, **275**:223-228.
10. Protti A, Russo R, Tagliabue P, Vecchio S, Singer M, Rudiger A, Foti G, Rossi A, Mistraletti G, Gattinoni L: Oxygen consumption is depressed in patients with lactic acidosis due to biguanide intoxication. *Crit Care* 2010, **14**:R22.
11. Protti A, Fortunato F, Monti M, Vecchio S, Gatti S, Comi GP, Giuseppe RD, Gattinoni L: Metformin overdose, but not lactic acidosis per se, inhibits oxygen consumption in pigs. *Crit Care* 2012, **16**:R75.
12. Seidowsky A, Nseir S, Houdret N, Fourrier F: Metformin-associated lactic acidosis: a prognostic and therapeutic study. *Crit Care Med* 2009, **37**:2191-2196.
13. Protti A, Carré J, Frost MT, Taylor V, Stidwill R, Rudiger A, Singer M: Succinate recovers mitochondrial oxygen consumption in septic rat skeletal muscle. *Crit Care Med* 2007, **35**:2150-2155.
14. Hinke SA, Martens GA, Cai Y, Finsl J, Heimberg H, Pipeleers D, Van de Casteele M: Methyl succinate antagonises biguanide-induced AMPK-activation and death of pancreatic beta-cells through restoration of mitochondrial electron transfer. *Br J Pharmacol* 2007, **150**:1031-1043.

doi:10.1186/cc11664

Cite this article as: Orban J-C, et al.: Metformin overdose: time to move on. *Critical Care* 2012, **16**:164.